Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 21 | 2023 | 787 | 6.260 |
Why?
|
| Heart Failure | 12 | 2024 | 2516 | 2.930 |
Why?
|
| Heart-Assist Devices | 8 | 2024 | 1171 | 2.630 |
Why?
|
| Glomerular Filtration Rate | 9 | 2022 | 602 | 2.060 |
Why?
|
| Acute Kidney Injury | 6 | 2022 | 739 | 1.920 |
Why?
|
| Kidney | 9 | 2024 | 2146 | 1.640 |
Why?
|
| Renal Replacement Therapy | 4 | 2021 | 135 | 1.160 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 960 | 1.160 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 2195 | 1.060 |
Why?
|
| Renal Dialysis | 8 | 2023 | 945 | 1.000 |
Why?
|
| Kidney Function Tests | 2 | 2022 | 192 | 0.960 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2023 | 128 | 0.920 |
Why?
|
| Hematinics | 1 | 2023 | 109 | 0.830 |
Why?
|
| Hypernatremia | 1 | 2022 | 33 | 0.830 |
Why?
|
| Ficus | 1 | 2021 | 3 | 0.820 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 849 | 0.810 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2021 | 159 | 0.750 |
Why?
|
| Vascular Diseases | 1 | 2022 | 246 | 0.740 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 151 | 0.730 |
Why?
|
| Nephrology | 1 | 2022 | 151 | 0.720 |
Why?
|
| Hospitalization | 6 | 2022 | 2083 | 0.720 |
Why?
|
| Blood Volume | 1 | 2020 | 100 | 0.710 |
Why?
|
| Creatinine | 4 | 2022 | 531 | 0.700 |
Why?
|
| Patient Care Management | 1 | 2020 | 94 | 0.690 |
Why?
|
| Blood Pressure | 3 | 2023 | 1467 | 0.660 |
Why?
|
| Anemia | 2 | 2021 | 689 | 0.660 |
Why?
|
| Kidney Tubules | 1 | 2018 | 137 | 0.650 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 462 | 0.640 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 263 | 0.640 |
Why?
|
| Heart Ventricles | 1 | 2023 | 846 | 0.630 |
Why?
|
| Serum Albumin | 1 | 2018 | 257 | 0.620 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 610 | 0.620 |
Why?
|
| Echocardiography | 1 | 2023 | 1182 | 0.600 |
Why?
|
| Iron | 1 | 2020 | 376 | 0.590 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 342 | 0.580 |
Why?
|
| Hospital Mortality | 3 | 2019 | 1274 | 0.570 |
Why?
|
| Heart Transplantation | 2 | 2022 | 908 | 0.550 |
Why?
|
| Patient Readmission | 1 | 2020 | 548 | 0.530 |
Why?
|
| Interleukin-1 | 1 | 2017 | 461 | 0.530 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.500 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 261 | 0.490 |
Why?
|
| Humans | 41 | 2024 | 261506 | 0.480 |
Why?
|
| Protective Agents | 1 | 2014 | 51 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1054 | 0.470 |
Why?
|
| Cohort Studies | 7 | 2023 | 9244 | 0.470 |
Why?
|
| Depressive Disorder | 1 | 2017 | 557 | 0.460 |
Why?
|
| Plasma Exchange | 1 | 2014 | 117 | 0.450 |
Why?
|
| United States | 11 | 2023 | 15433 | 0.410 |
Why?
|
| Atherosclerosis | 1 | 2020 | 935 | 0.410 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2011 | 73 | 0.380 |
Why?
|
| Cystatin C | 2 | 2021 | 54 | 0.360 |
Why?
|
| Nutritional Status | 1 | 2011 | 337 | 0.340 |
Why?
|
| Retrospective Studies | 12 | 2024 | 37905 | 0.320 |
Why?
|
| Depression | 1 | 2017 | 1715 | 0.310 |
Why?
|
| Prevalence | 5 | 2022 | 3260 | 0.300 |
Why?
|
| Inflammation | 1 | 2017 | 2522 | 0.290 |
Why?
|
| Risk Factors | 8 | 2024 | 17523 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 2403 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5542 | 0.240 |
Why?
|
| Adult | 10 | 2022 | 77950 | 0.240 |
Why?
|
| Male | 17 | 2022 | 123000 | 0.240 |
Why?
|
| Glucaric Acid | 1 | 2023 | 12 | 0.230 |
Why?
|
| Middle Aged | 14 | 2022 | 86204 | 0.220 |
Why?
|
| Japan | 1 | 2023 | 227 | 0.220 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2138 | 0.220 |
Why?
|
| Ferric Compounds | 1 | 2023 | 73 | 0.220 |
Why?
|
| Aged | 13 | 2021 | 70117 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2022 | 12873 | 0.200 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 69 | 0.200 |
Why?
|
| Female | 17 | 2022 | 141928 | 0.200 |
Why?
|
| Isoquinolines | 1 | 2021 | 116 | 0.190 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 103 | 0.190 |
Why?
|
| Sodium | 1 | 2022 | 353 | 0.190 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 356 | 0.180 |
Why?
|
| Fibrosis | 1 | 2023 | 793 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2022 | 2203 | 0.180 |
Why?
|
| Quality of Life | 3 | 2022 | 4532 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 257 | 0.180 |
Why?
|
| Glycine | 1 | 2021 | 289 | 0.170 |
Why?
|
| Incidence | 2 | 2020 | 5673 | 0.170 |
Why?
|
| Ezetimibe | 1 | 2019 | 101 | 0.170 |
Why?
|
| Prognosis | 6 | 2021 | 21713 | 0.170 |
Why?
|
| Survival Rate | 4 | 2021 | 12221 | 0.170 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 755 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 321 | 0.160 |
Why?
|
| Systole | 1 | 2018 | 196 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2019 | 228 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 109 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 140 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2023 | 32848 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 435 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 586 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 341 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 29902 | 0.140 |
Why?
|
| Reference Values | 1 | 2018 | 1099 | 0.140 |
Why?
|
| Mortality | 1 | 2018 | 343 | 0.140 |
Why?
|
| Lipids | 1 | 2020 | 644 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 3719 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 945 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2021 | 6869 | 0.130 |
Why?
|
| Uromodulin | 1 | 2014 | 13 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 2170 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 109 | 0.120 |
Why?
|
| Logistic Models | 1 | 2021 | 3441 | 0.120 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2013 | 35 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1945 | 0.110 |
Why?
|
| Models, Biological | 1 | 2021 | 3254 | 0.110 |
Why?
|
| Vascular Calcification | 1 | 2012 | 50 | 0.100 |
Why?
|
| Medicare | 3 | 2021 | 860 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1362 | 0.090 |
Why?
|
| Nutritional Requirements | 1 | 2011 | 185 | 0.090 |
Why?
|
| Obesity | 1 | 2022 | 2884 | 0.090 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 592 | 0.090 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 397 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 14889 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4892 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1085 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2012 | 665 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 4988 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2013 | 1863 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2018 | 9180 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 4971 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.060 |
Why?
|
| Mathematical Concepts | 1 | 2021 | 13 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 60 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4320 | 0.050 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 151 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 295 | 0.040 |
Why?
|
| Health Surveys | 1 | 2021 | 402 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 291 | 0.040 |
Why?
|
| Equipment Design | 1 | 2021 | 1204 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 378 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6311 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 2316 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 752 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 714 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 178 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4314 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 462 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 6009 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 15193 | 0.010 |
Why?
|